Abstract. Laryngeal squamous cell carcinoma (LSCC) and hypopharyngeal squamous cell carcinoma (HPSCC) are two types of head and neck cancers with high incidence rates and relatively poor prognoses. The aim of the present study was to determine the effects of microRNA (miR/miRNA)-136-5p and its downstream target, Rho-associated coiled-coil containing protein kinase 1 (ROCK1), on LSCC and HPSCC progression and cisplatin sensitivity. The miRNA and protein expression levels in head and neck cancer cell lines were evaluated using reverse transcription-quantitative PCR and western blotting, respectively. MTT, wound healing assays, transwell assays and flow cytometry analysis were performed to measure cell properties. The binding between miR‑136‑5p and ROCK1 was detected using a dual-luciferase reporter assay. Autophagy double-labeled adenoviral infection assays were used to assess cell autophagy. The results showed that miR‑136‑5p was expressed in LSCC and HPSCC cells. Functional experiments showed that the expression of miR‑136‑5p in LSCC and HPSCC cells was negatively correlated with cell viability, invasion and migration. Additionally, miR‑136‑5p overexpression inhibited epithelial-mesenchymal transition, whereas miR‑136‑5p knockdown had the opposite effect. Dual-luciferase reporter assays confirmed the targeting relationship between miR‑136‑5p and ROCK1. miR‑136‑5p overexpression increased the cisplatin sensitivity of LSCC and HPSCC cells by reducing cell viability, as well as promoting cell apoptosis and autophagy, miR‑136‑5p overexpression decreased the expression levels of its downstream target ROCK1 and attenuated activity of the Akt/mTOR signaling pathway in cisplatin-treated LSCC and HPSCC cells. Conversely, miR‑136‑5p knockdown increased ROCK1 levels and decreased cisplatin sensitivity of the LSCC and HPSCC cells by increasing cell viability and inhibiting cell apoptosis, which was reversed by ROCK1 inhibition using the ROCK1 inhibitor, Y27632. Taken together, the results showed that the miR‑136‑5p/ROCK1 axis inhibits cell invasion and migration, and increases the sensitivity of LSCC and HPSCC cells to cisplatin.

Introduction

Head and neck cancer is one of the most common types of cancer worldwide which includes the mouth, pharynx (nasopharynx, oropharynx and hypopharynx), larynx and paranasal sinus. According to the biological characteristics of head and neck cancer, it can be divided into several types. The most common type is head and neck squamous cell carcinoma (HNSCC), which accounts for >95% of all cases of head and neck cancer (1). HNSCC is the sixth most common type of cancer worldwide, with 600,000 cases diagnosed each year and a mortality rate of 40-50% (2,3). The majority of patients with locally advanced HNSCC usually develop a locoregional recurrence and/or distant metastases, and only a few patients with a locoregional recurrence may recover following treatment surgery and/or re-irradiation (3). Overall, the 5-year survival rate for patients with HNSCC has remained at 40-60% and is accompanied by a relatively poor prognosis (1,4,5). Laryngeal squamous cell carcinoma (LSCC) and hypopharyngeal squamous cell carcinoma (HPSCC) are two types of HNSCC with high incidence rates and a relatively poor prognosis following treatment (6-8). Although multiple proteins and pathways have been shown to be associated with the development of LSCC and HPSCC, the exact molecular mechanisms of action and potential therapeutic targets affecting proliferation and migration remain to be elucidated (9). MicroRNAs (miRNAs/miRs) are noncoding small RNA molecules that regulate the expression of target genes by binding to the 3'-untranslated region (UTR). miRNAs are involved in various biological processes including cell proliferation, apoptosis, invasion and migration (10). Various
miRNAs exhibit altered expression levels in cancers and serve crucial roles in the development of several types of cancer (11). Previous studies have found that the expression levels of miR-136 are significantly decreased at the tumor site and that miR-136 acts as a tumor suppressor in various tumor types, participating in the development of tumors by regulating the expression levels of downstream apoptosis-related genes (12,13). Additionally, miR-136 has also been found to be associated with cisplatin resistance in human epithelial ovarian and gastric cancers (14,15). Therefore, miR-136 may be a potential target for cancer therapy.

A previous study reported the relationship between miR-136 and Rho-associated coiled-coil containing protein kinase (ROCK) 1 (16,17). ROCK1, one of the isoforms of the ROCK, is a downstream effector of Rho A and is activated when it selectively binds to GTP (18,19). Activated ROCK interacts with the actin cytoskeleton to promote the formation of stress fibers and focal adhesions, which in turn promote the metastatic ability of tumor cells (20-22). ROCK overexpression has been reported to be associated with the progression of various malignancies, including bladder cancer, liver cancer and breast cancer (23,24). ROCK downregulation inhibits tumor growth and metastasis, and enhances the efficacy of cisplatin (25-27). In addition, the epithelial-mesenchymal transition (EMT) is a key process which often precedes and facilitates local invasion, vascular migration and distant metastasis of tumors (28). A previous study has shown that the ROCK pathway is not only involved in the proliferation, migration, adhesion and morphological changes of various cell types, but also in the EMT of tumor cells (22). ROCK serves a key role in TGF-β-induced EMT, which promotes mesenchymal transformation by rapidly activating RhoA-dependent signaling pathways (29). Therefore, ROCK serves a crucial role in cancer development.

Based on the aforementioned points, the regulatory mechanism of action behind the miR-136/ROCK1 axis in LSCC and HPSCC were investigated in the present study and its role in cell invasion and migration, as well as cisplatin sensitivity, were assessed.

**Materials and methods**

**Cell cultures, transfection and treatment.** FaDu cells were purchased from Procell and cultured in an incubator at 37°C and 5% CO₂ in minimum essential media (MEM, Sigma-Aldrich; Merck KGaA) containing 10% FBS (HyClone, GE Healthcare Life Sciences). FD-LSC-1 cells were obtained from Fudan University, China, and cultured in a BEBM (Lonza GE Healthcare Life Sciences). FD-LSC-1 cells were obtained from Fudan University, China, and cultured in a BEBM without serum and 5% CO₂ purchased from Procell and cultured in an incubator at 37°C in an incubator with 5% CO₂.

The sequences for the miRNA mimics and inhibitors were as follows: hsa-miR-136-5p mimics, 5'-ACUCAUUGGUGUUUGAGUGAGGA-3'; 5'-CAUCAUCAAAACAAAAUGAGGU-3'; NC mimics, 5'-UUUUCGAAGUGUCACGUTT-3'; 5'-ACGUGACACGUUCCGAGAATTT-3'; hsa-miR-136-5p inhibitor, 5'-UCCUCAUCAUACAAUCUGAGGU-3'; NC inhibitor, 5'-UGUUAUCACAAUGAUCAC-3'. The sequences were purchased from Jintuosi Biological Technology Co., Ltd.

**Reverse transcription-quantitative PCR (RT-qPCR).** Total RNA was extracted from cells using a Total RNA extraction kit (Tiangen Biotech, Co., Ltd.). cDNA was synthesized using an RNase inhibitor (Tiangen Biotech, Co., Ltd.), Super M-MLV reverse transcriptase (BioTeke Corporation), 5X PCR buffer and dNTP (2.5 mM each). The miR-136-5p primer used for reverse transcription was: 5'-TTGGTCTTGTGGCAGGGTCGAGGTTATCCGACCAGGCGA-3'. The temperature protocol that was used for reverse transcription was: 37°C for 30 min, 42°C for 30 min and 70°C for 15 min. To detect the expression levels of miRNA-136-5p, qPCR was performed using PCR Master Mix (Tiangen Biotech, Co., Ltd.), SYBR-Green (Beijing Solarbio Science & Technology Co., Ltd.) and specific primers for the target genes. The thermocycling conditions used for qPCR were as follows: 94°C for 4 min, 40 cycles of 94°C for 15 sec, 60°C for 20 sec and 72°C for 4 min, and 72°C for 15 sec. The 2^-ΔΔCq comparative method was used for data analysis (30). SS ribosomal RNA (rRNA) was used as the internal control to normalize the expression levels of genes.

**Cell viability assay.** MTT assays were performed to determine the cell viability. Briefly, cells were seeded in 96-well plates at a density of 4x10^3 cells per well. Subsequently, MTT (0.5 mg/ml) was added to each well. After incubating for 4.5 h at 37°C in an incubator with 5% CO₂, the supernatant was removed and 150 µl DMSO was added to each well to dissolve the purple crystals. Cells were immersed in the dark for 10 min and the optical density values at 570 nm were measured using a Microplate Reader (Biotek Instruments, Inc.).

**Cell migration assay.** Wound healing assays were performed to assess cell migration. The cells of each group were cultured to the fusion state (90% confluence). After transfection for 24 h as aforementioned, FaDu cells were cultured in a minimum essential media without serum and treated with 1 µg/ml mitomycin C (Sigma-Aldrich; Merck KGaA) for 1 h. FD-LSC-1 cells were cultured in a BEBM without serum and treated with 1 µg/ml mitomycin C for 1 h. Subsequently, the...
cells in each group were scratched with a 200 µl pipette tip and washed with serum-free medium to remove cell debris. After scratching, serum-free medium was used for cell culture and pictures were taken under a light microscope (magnification, x100; Olympus Corporation) to assess wound closure at 0 and 24 h.

**Invasion assay.** Cell invasion was detected using a Transwell assay. Briefly, Transwell chambers (Corning, Inc.) pre-coated with Matrigel were placed in 24-well plates. Culture medium (MEM medium for FaDu cells and BEBM medium for FD-LSC-1 cells, 800 µl) supplemented with 30% FBS was added to the lower chamber. Cell suspension in 200 µl serum-free media was added to the upper chamber at a density of 1.5x10^4 cells/well. After incubation in a cell culture incubator at 37˚C with 5% CO₂ for 24 h, the transwell chambers were washed three times with PBS to remove non-invading cells. The cells on the lower chamber were fixed with 4% paraformaldehyde at room temperature for 25 min and then stained with 0.4% crystal violet solution for 5 min at room temperature. Cells on lower chamber were counted under an inverted light microscope (magnification, x200; Olympus Corporation). A total of five fields were selected for each sample and the mean cell numbers was presented.

**Western blotting analysis.** The protein expression levels were detected using western blotting. Briefly, total protein was extracted from cells using RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) and phenylmethanesulfonyl fluoride protease inhibitor (Beijing Solarbio Science & Technology Co., Ltd.). Protein concentration in the lysate was quantified using a BCA protein concentration assay kit (Beijing Solarbio Technology Co., Ltd.). Protein concentration in the lysate was 1:1,000; Affinity Biosciences), microtubule-associated protein 1 light chain 3 (LC3II/I; cat. no. A7198; 1:1,000; Santa Cruz Biotechnology, Inc.). After incubating with horseradish peroxidase-conjugated goat anti-rabbit/mouse secondary antibodies (1:5,000; cat. nos. A0208 and A0216; Beyotime Institute of Biotechnology) for 45 min at 37˚C, signals were visualized using enhanced chemiluminescence solution (Beyotime Institute of Biotechnology). The expression levels of protein were normalized to β-actin. The value of each control was adjusted to 1 in each individual repeat of the western blot, therefore the mean value of the control is always 1.

**Dual-luciferase reporter assay.** The binding site of miR-136-5p and ROCK1 was predicted using TargetScanHuman 7.2 (http://www.targetscan.org/vert_72/). miR-136-5p was searched and the multiple genes that miR-136-5p may target were obtained. UTRs were also searched between ROCK1 and miR-136-5p to obtain the targeted binding sequence between miR-136-5p and ROCK1.

For the verification of the relationship between miR-136-5p and ROCK1, the wild-type (wt) ROCK1-3'UTR sequence and the mutant (mut) ROCK1-3'UTR sequence were cloned into the pmirGLO dual-luciferase reporter vectors (GenScript Biotech Corporation) to construct pmirGLO-ROCK1-3'UTR-wt and pmirGLO-ROCK1-3'UTR-mut plasmids. 293T cells were harvested and seeded in 12-well plates. Subsequently, the plasmids were co-transfected with miR-136-5p mimics/mimic-NC or miR-136-5p inhibitor/inhibitor-NC into 293T cells using Lipofectamine® 2000 reagent. After 48 h of incubation, the transfected cells were immediately harvested and assayed for luciferase activity using the dual-luciferase reporter assay system (Promega Corporation) according to the manufacturer’s protocol. Firefly luciferase activity was normalized to Renilla luciferase activity.

**Apoptosis assay.** Apoptosis was detected using flow cytometry analysis. The Annexin V-FITC apoptosis detection kit (Beyotime Institute of Biotechnology) was used to detect apoptosis. Cells were harvested and adjusted to a density of 1x10⁶ cells/tube. Subsequently, cells were treated with 5 µl Annexin V-FITC and 10 µl PI and incubated for 15 min at room temperature in the dark. Finally, cells stained with Annexin V-FITC and PI were detected using flow cytometry (ACEA Bioscience, Inc.) and analyzed using NovoExpress 1.2.5 (ACEA Biosciences, Inc.).

**Autophagy double-labeled adenovirus infection assay.** Cells were seeded in a 24-well plate (5x10⁵ cells) and infected with RFP-GFP-LC3-labeled adenovirus (Hanbio Biotechnology Co., Ltd.) at a multiplicity of infection of 50. After incubating for 24 h in an incubator at 37˚C supplied with 5% CO₂, the supernatant of the medium containing the virus solution was discarded and replaced with complete medium (MEM medium containing 10% FBS for FaDu cells and BEBM medium containing 10% FBS for FD-LSC-1 cells). After incubating for 24 h in an incubator at 37˚C, images were taken using a laser-scanning confocal microscope equipped with the FV10-ASW system (magnification, x400; Olympus Corporation).
YANG et al: miR-136-5P/ROCK1 AXIS ENHANCES CISPLATIN SENSITIVITY IN HEAD AND NECK CANCER CELLS

Statistical analysis. Unpaired t-tests were used to analyze differences between two groups. Comparisons among multiple groups were analyzed using a one-way ANOVA with Tukey's multiple comparisons test. The experiments were performed at least three times. Data are presented as the mean ± SD and analyzed using GraphPad version 8.0. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-136-5p suppresses the viability, invasion and migration of LSCC and HPSCC cells. To detect the expression levels of miR-136-5p in LSCC and HPSCC cells, RT-qPCR was performed. The results showed that miR-136-5p was expressed in FD-LSC-1 and FaDu cells (Fig. 1A). The effects of miR-136-5p on LSCC and HPSCC cell functions were further investigated. Cells were transfected with miR-136-5p mimics, mimics-NC, miR-136-5p inhibitor or inhibitor-NC for 24 h. miR-136-5p mimics increased the expression levels of miR-136-5p in FD-LSC-1 and FaDu cells, whereas miR-136-5p inhibitor decreased miR-136-5p levels (Fig. 1B and C, respectively; P<0.05). MTT assays were subsequently performed to detect the viability of the transfected cells. The results showed that miR-136-5p overexpression reduced the cell viability of FD-LSC-1 and FaDu cells, whereas miR-136-5p downregulation promoted cell viability compared with the respective NC transfected cells (Fig. 2A, P<0.05). Wound healing and transwell invasion assays were used to measure cell migration and invasion, respectively. The results showed that miRNA-136-5p overexpression reduced cell invasion and migration, whereas miRNA-136-5p knockdown increased the migratory and invasive capacity of FD-LSC-1 and FaDu cells compared with the corresponding NC groups (Fig. 2B-F; all P<0.05). Western blotting was performed to measure E-cadherin, N-cadherin and vimentin protein expression levels in the transfected cells. As shown in Fig. 2G, miR-136-5p overexpression increased the protein expression of E-cadherin but decreased the N-cadherin and vimentin levels compared with the mimics-NC group in both cell lines (all P<0.05). Similarly, miRNA-136-5p inhibition decreased E-cadherin levels and increased N-cadherin and vimentin levels compared with the inhibitor-NC group (P<0.05). These results suggested that miR-136-5p reduces cell viability, invasion and migration in LSCC and HPSCC cells.

miRNA-136-5p directly targets ROCK1 in LSCC and HPSCC cells. ROCK1 was identified as a potential target of miR-136-5p, which was confirmed by the luciferase reporter assays. A ROCK1-wt luciferase plasmid containing the potential miR-136-5p binding sites as well as a mut version (ROCK1-mut) was generated (Fig. 3A). As shown in Fig. 3B, the luciferase activity in LSCC and HPSCC cells transfected with ROCK1-wt plasmid was significantly reduced by the transfection of miR-136-5p mimics (P<0.05), whereas no alteration was observed in the luciferase activity of cells transfected with ROCK1-mut plasmid (P>0.05), which suggested that miR-136-5p may bind to the 3’UTR of ROCK1.

miR-136-5p overexpression increases the cisplatin sensitivity of LSCC and HPSCC cells. Cisplatin is commonly used as a chemotherapeutic drug for several types of cancer. To explore the role of miR-136-5p on the sensitivity of LSCC and HPSCC cells to cisplatin, cells were transfected with miR-136-5p mimics or mimics-NC for 24 h and then treated with cisplatin (2.6 µM) for 24 h. The results of cell viability analysis using

---

**Figure 1.** The expression levels of miR-136-5p in LSCC and HPSCC cells. (A) The expression level of miR-136-5p in LSCC and HPSCC cells. Following transfection of the cells with (B) miR-136-5p mimics, mimics-NC; or (C) miR-136-5p inhibitor or inhibitor-NC for 24 h, the expression levels of miR-136-5p were measured using reverse transcription-quantitative PCR. Data are presented as the mean ± SD, n=3. *P<0.05. HPSCC, head and neck squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; miR, microRNA; NC, negative control.
MTT assays showed a decrease in the cell viability in response to cisplatin treatment following miR-136-5p overexpression (Fig. 4A; P<0.05). Apoptosis analysis measured by flow cytometry showed that miR-136-5p overexpression combined with cisplatin significantly promoted apoptosis (Fig. 4B and C; P<0.05). The effect of cisplatin coupled with miR-136-5p on autophagy was also assessed. The results showed that miR-136-5p upregulation resulted in the increase of free yellow puncta (indicating autophagosome) and red puncta (indicating autolysosomes), indicating that autophagosome formation was promoted and the autophagy flux was induced by miR-136-5p upregulation (Fig. 4D and 4E). As shown in Fig. 4F, miR-136-5p overexpression significantly decreased the protein expression levels of ROCK1 and P62, as well as the ratios of p-Akt, p-GSK-3β and p-mTOR to their unphosphorylated versions, but increased LC3II/I levels in LSCC and HPSCC cells (all P<0.05). miR-136-5p downregulation decreases the cisplatin sensitivity of LSCC and HPSCC cells by targeting ROCK1. The effects of the miR-136-5p/ROCK axis on the sensitivity of LSCC and HPSCC cells to cisplatin were investigated. Cells were transfected with miR-136-5p inhibitor or inhibitor-NC for 24 h and then treated with cisplatin (2.6 µM) and/or Y27632 (25 µM, ROCK inhibitor) for 24 h. As shown in Fig. 5A-C, miR-136-5p downregulation promoted cisplatin-treated cell viability and inhibited apoptosis whereas ROCK1 knockdown reversed the effects of miR-136-5p downregulation on cisplatin-treated cell viability and inhibited apoptosis whereas ROCK1 knockdown reversed the effects of miR-136-5p downregulation on cisplatin-treated cell viability and inhibited apoptosis (all P<0.05). Additionally, cleaved caspase-3, Bax and Bcl-2 are important regulators of apoptosis. Cleaved caspase-3 and Bax promote apoptosis whereas Bcl-2 inhibits apoptosis (31,32). The results of western blot analysis showed that miR-136-5p downregulation promoted caspase-treated cell viability and inhibited apoptosis whereas ROCK1 knockdown reversed the effects of miR-136-5p downregulation on cisplatin-treated cell viability and apoptosis (all P<0.05).
ROCK1 downregulation reversed the effects of miR-136-5p knockdown on the protein expression levels (Fig. 5D; all P<0.05).

**Discussion**

The role of miRNAs in cancer has been extensively investigated, particularly their downstream targets, biological functions and significance in cancer development and progression (11). miR-136 has been reported to be involved in the development of several types of cancer through targeting downstream effector molecules and is associated with cisplatin resistance in cancer (14,33). Based on the important roles of miR-136-5p in cancer development, the potential regulatory mechanisms of action of miR-136-5p in LSCC and HPSCC progression, as well as cisplatin sensitivity were investigated. In the present study, it was shown that miR-136-5p inhibited cell invasion and migration, and increased the sensitivity of LSCC and HPSCC to cisplatin by repressing ROCK1 expression.

miR-136 is a negative regulator of cancer progression and its expression levels are reduced during the development of various types of cancer, including gastric cancer, colon cancer and breast cancer (33-35). Functional experiments indicate that miR-136 can inhibit cell proliferation, invasion and metastasis and induce apoptosis during cancer progression (15,35,36). In particular, it has been reported that downregulation of miR-136-5p markedly reduces cell viability, invasion and migration in LSCC (37). Consistent with the previous results, the present study identified the suppressive functions of miR-136-5p on cell viability, invasion and migration during LSCC and HPSCC progression. The EMT is an important process that regulates cancer development, initiation and metastatic dissemination (38). A significant feature of EMT is the reduction in epithelial markers, usually indicated by the presence of E-cadherin and the elevation of mesenchymal markers, such as N-cadherin and vimentin, resulting in an invasive phenotype (39). Yan et al (35) investigated the effects of miR-136 on the EMT process in breast cancer. The results showed that miR-136 overexpression significantly increases E-cadherin levels but decreases vimentin levels, suggesting that miR-136 suppresses EMT. In the present study, it was shown that miR-136-5p overexpression significantly increased E-cadherin expression levels and decreased N-cadherin and vimentin levels, whereas miR-136-5p downregulation reversed these changes. This suggested that miR-135-5p suppresses the EMT process in LSCC and HPSCC cells. Phenotypic changes between epithelial and mesenchymal are widely recognized as important factors influencing tumor cell invasion and metastasis (40). Thus, miR-136-5p may inhibit cell migration and invasion through mechanisms dependent on EMT (41). Additionally, a previous study found that Bcl-2 is a downstream target of miR-136-5p and that miR-136-5p promotes apoptosis by promoting the degradation of the apoptosis inhibitor, Bcl-2, which is negatively associated with cancer development (42). Collectively, the results indicated the tumor-suppressive function of miR-136-5p on LSCC and HPSCC development.

TargetScan 7.2 predicted that miR-576-3p targeted ROCK1. It has been reported that ROCK1 is a downstream target of miR-136-5p and that the miR-136-5p/ROCK1 axis participates in the inflammatory response induced by cerebral
ischemia/reperfusion injury, as well as in the proliferation and invasion of LSCC cells (16,17). The present study also confirmed this relationship using a dual-luciferase reporter assay. ROCK1 is a serine-threonine protein kinase, which phosphorylates a variety of downstream target proteins through interactions with Rho GTPases, to promote the generation of actin-myosin mediated contractile forces, thereby controlling cell mobility, metastasis and invasion (22,43). Previous studies have indicated that ROCK1 is associated with cancer progression and its expression levels are elevated in several types of cancer (44-46). For example, in prostate cancer, ROCK expression levels have been reported to be significantly increased and this was associated with increased cell proliferation and migration (47). Additionally, it has been reported that ROCK1 expression is positively correlated with tumor size and lymph node metastasis, and that downregulation of ROCK1 inhibits cell proliferation, migration and invasion of LSCC cells (48,49). The present study demonstrated that miR-136-5p overexpression increases the cisplatin sensitivity of laryngeal squamous cell carcinoma and head and neck squamous cell carcinoma cells. (A) After cells were transfected with miR-136-5p mimics or mimics-NC and treated with cisplatin (2.6 µM) for 24 h, cell viability was detected using MTT assays, n=6. (B) Flow cytometric detection of apoptosis using annexin V-FITC/PI staining and (C) quantification of apoptosis. Autophagy was detected using an autophagy double-labeled adenovirus infection assay in (D) FD-LSC-1 and (E) FaDu cells, scale bar=50 µm. Free yellow puncta indicates the autophagosome, free red puncta indicates the autophagolysosome. (F) The protein expression levels of ROCK1, p-Akt/Akt (Ser473), GSK-3β, p-GSK-3β (Ser9), p-mTOR (S2448)/mTOR, LC3II/I and P62 were measured using western blot analysis and normalized to the levels of β-actin. Data are presented as the mean ± SD, n=3. *P<0.05. GSK-3β, glycogen synthase kinase-3β; LC3, microtubule-associated protein 1 light chain 3; miR, microRNA; mTOR, mammalian target of rapamycin; NC, negative control; p-, phosphorylated.

Figure 4. miR-136-5p overexpression increases the cisplatin sensitivity of laryngeal squamous cell carcinoma and head and neck squamous cell carcinoma cells. (A) After cells were transfected with miR-136-5p mimics or mimics-NC and treated with cisplatin (2.6 µM) for 24 h, cell viability was detected using MTT assays, n=6. (B) Flow cytometric detection of apoptosis using annexin V-FITC/PI staining and (C) quantification of apoptosis. Autophagy was detected using an autophagy double-labeled adenovirus infection assay in (D) FD-LSC-1 and (E) FaDu cells, scale bar=50 µm. Free yellow puncta indicates the autophagosome, free red puncta indicates the autophagolysosome. (F) The protein expression levels of ROCK1, p-Akt/Akt (Ser473), GSK-3β, p-GSK-3β (Ser9), p-mTOR (S2448)/mTOR, LC3II/I and P62 were measured using western blot analysis and normalized to the levels of β-actin. Data are presented as the mean ± SD, n=3. *P<0.05. GSK-3β, glycogen synthase kinase-3β; LC3, microtubule-associated protein 1 light chain 3; miR, microRNA; mTOR, mammalian target of rapamycin; NC, negative control; p-, phosphorylated.
may also regulate cell metastasis and invasion by regulating the downstream target ROCK1 in LSCC and HPSCC cells.

Cisplatin is a systemic therapy, usually combined with radiation as a standard treatment of head and neck cancer (50). Cisplatin-based chemotherapy regimens are the most commonly used adjunctive therapy for several types of cancer (51). However, cisplatin resistance is a major barrier to therapeutic success (52). Thus, increasing the chemosensitivity to cisplatin may contribute to the successful treatment for various types of cancer. Zhao et al (14) demonstrated that the expression of miR-136 was associated with primary cisplatin resistance in human epithelial ovarian cancer. Studies have reported that miR-136 reversed cisplatin chemosensitivity in glioma cells through targeting downstream targets (53). The present study showed that miR-136-5p overexpression increased the sensitivity to cisplatin of LSCC and HPSCC cells by reducing cell viability and promoting apoptosis.

Figure 5. miR-136-5p downregulation decreased the cisplatin sensitivity of laryngeal squamous cell carcinoma and head and neck squamous cell carcinoma cells by targeting ROCK1. (A) After cells were transfected with miR-136-5p inhibitor or inhibitor-NC for 24 h, as well as with cisplatin (2.6 μM) and/or Y27632 (25 μM; ROCK inhibitor) for 24 h, cell viability was detected using MTT assays, n=6. (B) Flow cytometric detection of apoptosis using annexin V-FITC/PI staining and (C) quantification of apoptosis. (D) The protein expression levels of ROCK1, p-GSK-3β (Ser9)/GSK-3β, cleaved caspase-3, Bax and Bcl-2 were measured using western blot analysis and normalized to the levels of β-actin (D). Data are presented as the mean ± SD, n=3. *P<0.05. GSK-3β, glycogen synthase kinase-3β; miR, microRNA; NC, negative control; p-, phosphorylated; ROCK, Rho-associated coiled-coil-containing protein kinase.
p-mTOR axis negatively regulates autophagy (56). GSK-3β is a major downstream molecule of p-Akt that inhibits autophagy by activating mTOR (57). LC3-I is cleaved and lipidated to form LC3-II during autophagosome formation and LC3-II is a known autophagosomal marker in mammals (58). P62 is a selective autophagy substrate that can be continuously degraded by autophagy (59). Mathew et al (60) demonstrated that autophagy inhibited tumorigenesis by interfering with the p62 pathway, which is crucial for tumorigenesis. Wu et al (61) reported that autophagy decreases the sensitivity of lung adenocarcinomas to cisplatin treatment through the activation of the AMPK/mTOR signaling pathway. The present study showed that miR-136-5p overexpression combined with cisplatin decreased P62 levels and inhibited the Akt/mTOR pathway, a pathway that negatively regulates autophagy (62). The results suggested that miR-136-5p overexpression promoted autophagy, which is conducive to the inhibition of LSCC and HPSCC development, and the increase of cisplatin sensitivity of LSCC and HPSCC cells. Conversely, miR-136-5p knockdown decreased the sensitivity to cisplatin in both LSCC and HPSCC cells, while the inhibition of ROCK1 reversed the effects of miR-136-5p knockdown on cisplatin sensitivity, indicating that miR-136-5p may affect the cisplatin sensitivity of LSCC and HPSCC cells by targeting ROCK1. Collectively, the present study suggested that miR-136-5p renders LSCC and HPSCC cells more sensitive to cisplatin treatment and miR-136-5p and cisplatin combined promotes chemosensitivity through targeting ROCK1 in LSCC and HPSCC cells. Therefore, the miRNA-136-5p/ROCK axis may serve as a promising therapeutic target for the treatment of LSCC and HPSCC.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials statements
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
BY and FZ designed the study and wrote the manuscript. JZ and WY performed the data collection and confirmed the authenticity of all the raw data. XJ performed statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Chan JYK, Zhen G and Agrawal N: The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. Semin Cancer Biol 55: 1-7, 2019.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
3. Stenson B, Young RJ and Rischin D: Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol 52: 228-240, 2018.
4. Grégoire V, Lefebvre JL, Licitra L and Felip E; EHNS-ESMO-ESTRO Guidelines Working Group: Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v184-v186, 2010.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386, 2015.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
7. Fong PY, Tan SH, Lim WT, Tan EH, Ng QS, Sommat K, Tan DSW and Ang MK: Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). PLoS One 14: e0224665, 2019.
8. Cristina V, Herrera-Gómez RG, Szturz P, Espelt V and Siano M: Immunotherapies and future combination strategies for head and neck squamous cell carcinoma. Int J Mol Sci 20: 20, 2019.
9. Nowicka Z, Stawiski K, Tomasik B and Fendler W: Extracellular miRNAs as Biomarkers of Head and Neck Cancer Progression and Metastasis. Int J Mol Sci 20: 20, 2019.
10. Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol 23: 175-205, 2007.
11. Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol 4: 199-227, 2009.
12. Libbus BL and Johnson LA: The creeping vole, Microtus oregoni: Karyotype and sex-chromosome differences between two geographical populations. Cytogenet Cell Genet 47: 181-184, 1988.
13. Zhang Y, Li Y, Han L, Zhang P and Sun S: SUMO1P3 is associated clinical progression and facilitates cell migration and invasion through regulating miR-136 in non-small cell lung cancer. Biomed Pharmacother 113: 108686, 2019.
14. Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo G, Jiang J and Cui S: Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep 33: 591-598, 2015.
15. Yu L, Zhou QQ and Li DC: miR-136 triggers apoptosis in human gastric cancer cells by targeting AEG-1 and BCL2. Eur Rev Med Pharmacol Sci 22: 7521-7526, 2018.
16. Zhong Y, Yu C and Qin W: IncRNA SNHG14 promotes inflammatory response induced by cerebral ischemia/reperfusion injury through regulating miR-136-5p /ROCK1. Cancer Gene Ther 26: 234-247, 2019.
17. Zhang W, Shi J, Cheng C and Wang H: CircTIMELESS regulates the proliferation and invasion of lung squamous carcinoma cells via the miR-136-5p/ROCK1 axis. J Cell Physiol 235: 5962-5971, 2020.
18. Riento K and Ridley AJ: Rocks: Multifunctional kinases in cell migration. Nat Rev Mol Cell Biol 4: 446-456, 2003.
19. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kazukiza A, Morii N, et al: The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15: 1885-1893, 1996.
20. Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y and Narumiya S: p160ROCK, A Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 404: 118-124, 1997.
21. Del Peso L, Hernández-Alcoceba R, Embade N, Carnero A, Esteve P, Paje C and Lacal JC: Rho proteins induce metastatic properties in vivo. Oncogene 15: 3047-3057, 1997.
22. Narumiya S, Tanji M and Ishizaki T: Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28: 65-76, 2009.

23. Wang B, Li CC, Wong CM, Tung EK, Man K and Ng IO: Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 49: 1583-1594, 2009.

24. Morgan-Fisher M, Wewer UM and Yoneda A: Regulation of ROCK activity in cancer. J Histochem Cytochem 61: 185-198, 2013.

25. Bishop AL and Hall A: Rho GTPases and their effector proteins. Biochim J 348: 241-255, 2000.

26. Imamura F, Mukai M, Ayaki M and Akedo H: Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 91: 811-816, 2000.

27. Ohta T, Takahashi T, Shibuya T, Amida M, Henni N, Takahashi K and Kurachi H: Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells. Cancer Biol Ther 13: 25-33, 2012.

28. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.

29. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Artega CL and Moses HL: Transforming growth factor-beta mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27-36, 2001.

30. Livak KJ and Schmittgen TD: Analysis of relative gene expression using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

31. Cohen GM: Caspases: The executioners of apoptosis. Biochem J 326: 1-16, 1997.

32. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ and Green DR: The BCL-2 family reunión. Mol Cell 37: 299-310, 2010.

33. Zheng J, Ge P, Liu X, Wei J, Wu G and Li X: miR-136 inhibits gastric cancer-specific peritoneal metastasis by targeting HOXC10. Tumour Biol 39: 1010428317706207, 2017.

34. Ren H, Qi Y, Yin X and Gao J: miR-136 targets MIEN1 and HOXC10. Tumour Biol 39: 1010428317706207, 2017.

35. Yan M, Li X, Tong D, Han C, Zhao R, He Y and Jin X: miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol Rep 36: 65-71, 2016.

36. Yuan Q, Cao G, Li J, Zhang Y and Yang W: MicroRNA-136 inhibits colon cancer cell proliferation and invasion through targeting liver receptor homolog-1/Wnt signaling. Gene 628: 48-55, 2017.

37. Wang Z, Huang C, Zhang A, Lu C and Liu L: Overexpression of circRNA_100290 promotes the progression of laryngeal squamous cell carcinoma through the miR-136-5p/RAP2C axis. Biomed Pharmacother 125: 109874, 2020.

38. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1595-1564, 2011.

39. Cho ES, Kang HE, Kim NH and Yook JI: Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res 42: 14-24, 2019.

40. Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev 35: 645-654, 2016.

41. Kang W, Wang Q, Dai Y, Wang H, Wang M, Wang J, Zhang D, Sun P, Qi T, Jin X, et al: Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad5 axis. Cell Death Dis 11: 1038, 2020.

42. Young FE: Efficacy of new tests and the safety of the blood supply. Transfusion 30: 4-5, 1990.

43. Liu S, Goldstein RH, Scepansky EM and Rosenblatt M: Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 69: 8742-8751, 2009.

44. Liang H, Zhang C, Guan H, Liu J and Cui Y: IncRNA DANC4 promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p. J Cell Physiol 234: 7266-7278, 2019.

45. Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z and Huang JA: miR-335-5p inhibits TGF-β1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res 20: 225, 2019.

46. Hu C, Zhou H, Liu Y, Huang J, Liu W, Zhang Q, Tang Q, Sheng F, Li G and Zhang R: ROCK1 promotes migration and invasion of non small cell lung cancer cells through the PTEN/PI3K/AKT pathway. Int J Oncol 55: 833-844, 2019.

47. Gong H, Zhou L, Khelfat L, Qiu G, Wang Y, Mao K and Chen W: Rho-associated protein kinase (ROCK) promotes proliferation and migration of PC-3 and DU145 prostate cancer cells by targeting LIM kinase 1 (LIMK1) and matrix metalloproteinase-2 (MMP-2). Med Sci Monit 25: 3090-3099, 2019.

48. Zhang J, He X, Ma Y, Liu Y, Shi H, Guo W and Liu L: Overexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma. Int J Clin Exp Pathol 8: 244-251, 2015.

49. Liu Y, Liu J, Wang L, Yang X and Liu X: MicroRNA 195 inhibits cell proliferation, migration and invasion in laryngeal squamous cell carcinoma by targeting ROCK1. Mol Med Rep 16: 7154-7162, 2017.

50. Carlsøn L, Brattman SV, Sui LL and Spreefo A: The cisplatin total dose and concomitant radiation in locoregionally advanced head and neck cancer: Any recent evidence for dose efficacy? Curr Treat Options Oncol 18: 39, 2017.

51. Dasari S and Tchouwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 740: 364-374, 2014.

52. Amable L: Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 106: 27-36, 2016.

53. Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu Q, Cao K and Li Q: miR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J Neurooncol 120: 43-53, 2014.

54. Glick D, Barth S and Macleod KF: Autophagy: Cellular and molecular mechanisms. J Pathol 221: 3-12, 2010.

55. Yao Q, Chen J, Lv Y, Wang T, Zhang J, Fan J and Wang L: The significance of expression of autophagy-related gene Beclin-1, Bcl-2, and Bax in breast cancer tissues. Tumour Biol 32: 1163-1171, 2011.

56. Janku F, McConkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8: 528-539, 2011.

57. Azoulay-Alfaguter I, Elyra L, Avrahami L, Katz A and Eldar-Finkelman H: Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. Oncogene 34: 4613-4623, 2015.

58. Tanida I, Ueno T and Kominami E: LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 36: 2503-2518, 2004.

59. Bajaj R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhagot G, Gelinas C, et al: Autophagy suppresses tumorigenesis through elimination of p62. Cell 157: 1062-1079, 2009.

60. Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y, Bai YY, Cheng YZ, Nan KJ and Liang X: Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther 9: 6421-6431, 2015.

61. Xu Z, Han X, Ou D, Liu T, Li Z, Jiang G, Liu J and Zhang J: Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol 104: 575-587, 2020.